Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 126

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 126
---
 our facilities or personnel, or obtain funds through other arrangements that may require us to relinquish some
of our assets or rights to certain of our existing or future technologies, drug candidates, or products on terms not favorable to us.

Such
conditions raise substantial doubts about the Company’s ability to continue as a going concern. Management’s plan includes
raising funds from the issuance and sale of its common stock via its ATM program and other funding transactions. However, as mentioned
above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company
or will provide the Company with sufficient funds to meet its objectives. The Company’s financial statements do not include any
adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities
that may be required should the Company be unable to continue as a going concern.

Off-Balance
Sheet Arrangements and Contractual Obligations

None.

Item
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required
under this item.

Item
4. CONTROLS AND PROCEDURES

We
have carried out an evaluation, under the supervision and with the participation of management, including our principal executive officer
and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as that
term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended. Based on that evaluation, our principal executive
officer and principal financial officer have concluded that, as of March 31, 2025, which is the end of the period covered by this report,
our disclosure controls and procedures are effective at the reasonable assurance level in alerting them in a timely manner to material
information required to be included in our periodic reports with the SEC.

There
were no changes in our internal control over financial reporting identified in connection with the evaluation that occurred during the
period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over
financial reporting.

26

Our
management, including our chief executive officer and chief financial officer, does not expect that our disclosure controls and procedures
or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how